Impact of Progestin-only Contraception on Bleeding Patterns in Individuals Initiating GATT

Launched by UNIVERSITY OF CALIFORNIA, SAN DIEGO · Jan 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how progestin-only contraception affects bleeding patterns in individuals who are starting gender-affirming testosterone therapy (GATT). Many gender-diverse individuals use GATT to help alleviate feelings of gender dysphoria, and some may also want to use progestins to manage or suppress uterine bleeding. However, there isn’t enough research specifically focused on how these two treatments work together, which makes it hard for doctors to provide clear guidance. By observing individuals who start GATT with or without progestin, the researchers aim to gather important information about bleeding patterns and overall satisfaction.

To be eligible for this study, participants need to be English-speaking individuals aged between 18 and 62 who currently have a uterus and ovaries, and who want to start GATT and possibly a progestin within 14 days of beginning GATT. Those who have had surgery to remove their uterus or ovaries are not eligible. Participants can expect to share their experiences regarding bleeding and satisfaction during the trial, which will help doctors better understand how progestin use can affect those starting GATT. This study is currently recruiting participants, and the findings will help improve counseling for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • English-speaking currently have a uterus and ovaries
• • desire to initiate GATT
• • potential desire to initiate a progestin (within 14 days of GATT initiation)
• Exclusion Criteria:
• • previous gender-affirming surgery to remove their uterus and/or ovaries